OCA
HEPA

Octagon Capital Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

Octagon Capital Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,350
Closed -$337K – 39
2023
Q3 		$337K Sell
1,350
-1,750
-56% -$653K 0.05% 40
2023
Q2 		$1.63M Buy
+3,100
New +$1.9M 0.23% 36

Other funds holding HEPA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Octagon Capital Advisors's HEPA Position: Q4 2023 in Review

Octagon Capital Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q4 2023, closing a stake of 1,350 shares — an estimated $337K sold.

Octagon Capital Advisors first reported a position in HEPA in Q2 2023 and held it in 2 quarters. The position peaked at $1.63M in Q2 2023. 16 funds tracked by Wall St. Rank hold HEPA as of Q4 2023.

  • Octagon Capital Advisors reported no remaining Hepion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 1,350 Hepion Pharmaceuticals shares in Q4 2023, an estimated $337K.
  • Octagon Capital Advisors first reported a position in Hepion Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Octagon Capital Advisors's Hepion Pharmaceuticals position peaked at $1.63M in Q2 2023.
  • 16 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.